Cullinan Therapeutics, Inc. Common Stock

CGEMNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
17.69 USD
↗ 1.28 (7.80%)AT CLOSE (11:59 AM EDT)
17.58
↘ 0.11 (0.62%)
POST MARKET (AS OF 07:12 PM EDT)
Post Market
AS OF 07:12 PM EDT
17.58
↘ 0.11 (0.62%)
🔴Market: CLOSED

Cullinan Therapeutics, Inc. Common Stock (CGEM) is currently trading at $17.68. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jul 17, 2026.

Open?$16.06
High?$17.89
Low?$16.00
Prev. Close?$16.41
Volume?594.8K
Avg. Volume?1.2M
VWAP?$17.47
Rel. Volume?0.49x
Bid / Ask
Bid?$14.69 × 100
Ask?$20.35 × 100
Spread?$5.66
Midpoint?$17.52
Valuation & Ratios
Market Cap?1.0B
Shares Out?61.5M
Float?47.0M
Float %?79.6%
P/E Ratio?N/A
P/B Ratio?2.75
EPS?-$3.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
109
Market Cap
1.0B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cullinantherapeutics.com
Listed
2021-01-08
Address
ONE MAIN STREET
CAMBRIDGE, MA 02142
Phone: 617-410-4650
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
15
Piotroski F-Score?0/9Weak
Altman Z-Score?13.23Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.53%Squeeze Risk
Short Interest?10.6M
Days to Cover?6.6
Free Float47.0M
Avg Daily Volume1.6M
Settlement Date2026-06-30
Financial Health
Current Ratio?10.28Strong
Quick Ratio?10.28Strong
Cash Ratio?2.14Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
60
2.75CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-53.3%WEAK▾
ROA?
S&P
3
-48.4%WEAK▾
Cash Flow & Enterprise
FCF?$-178689000
Enterprise Value?$933.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist